{"id":"W2763073378","doi":"10.1200/jco.2017.35.15_suppl.tps5091","title":"PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Olaparib; Medicine; Enzalutamide; PARP inhibitor; Prostate cancer; Internal medicine; Oncology; Cancer; Cancer research; Poly ADP ribose polymerase; Polymerase; Gene; Androgen receptor; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068593,0.001162592,0.001258234,0.0003119531,0.0002518832,0.000964107,0.0008354608,0.0008597485,0.007965853],"category_scores_gemma":[0.001001463,0.0004938034,0.0009834816,0.0003655278,0.0007123812,0.0007380691,0.0005534748,0.002119583,0.0008452563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00054838,"about_ca_system_score_gemma":0.001041463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005721271,"about_ca_topic_score_gemma":0.001957223,"domain_scores_codex":[0.9997228,0.0001474708,0.00001168951,0.00004775884,0.00002671596,0.00004356969],"domain_scores_gemma":[0.9994954,0.00008048605,0.0001229251,0.00003203606,0.00002407419,0.0002450876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.930146,0.01006565,0.002721784,0.001223969,0.001180483,0.000157091,0.00008317704,0.001331409,0.009606109,0.0004782869,0.003428304,0.03957779],"study_design_scores_gemma":[0.9125681,0.08053125,0.002932372,0.00004795394,0.0003792172,0.0001640448,0.000035983,0.0005433153,0.0004332854,0.000330399,0.002015549,0.00001848533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776502,0.005383024,0.001090968,0.001179591,0.0004074222,0.005459526,0.003553706,0.0002623563,0.00501314],"genre_scores_gemma":[0.979755,0.002906886,0.001897204,0.0024686,0.0003042748,0.004217749,0.00372994,0.00003078804,0.004689616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007965853,"threshold_uncertainty_score":0.02664846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1398554968757785,"score_gpt":0.5108660853555113,"score_spread":0.3710105884797328,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}